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The Impact of Angiotensin-Converting Enzyme
Inhibitor Therapy on the Extracellular Collagen
Matrix During Left Ventricular Assist Device
Support in Patients With End-Stage Heart Failure
Stefan Klotz, MD,* A. H. Jan Danser, PHD,‡ Robert F. Foronjy, MD,* Mehmet C. Oz, MD,†
Jie Wang, MD, PHD,*§ Donna Mancini, MD,* Jeanine D’Armiento, MD, PHD,*
Daniel Burkhoff, MD, PHD*§
New York and Orangeburg, New York; and Rotterdam, the Netherlands
Objectives We hypothesized that angiotensin-converting enzyme inhibition (ACE-I) during left ventricular assist device
(LVAD) support in patients with end-stage heart failure prevents potentially deleterious effects on the extracellu-
lar matrix.
Background Left ventricular assist device-induced mechanical unloading increases myocardial collagen and stiffness and
may contribute to the low rate of recovery.
Methods Heart samples obtained before and after LVAD implantation were divided into groups depending on whether the
patients received (n  7) or did not receive (control; n  15) ACE-I. At transplant, ex vivo pressure-volume rela-
tionships were measured and chamber and myocardial stiffness constants determined. Myocardial tissue con-
tent of angiotensin (Ang) I and II, matrix metalloproteinase (MMP)-1, tissue inhibitor of MMPs (TIMP)-1, and total
and cross-linked collagen was measured.
Results Duration of support was comparable between ACE-I and control subjects (96  65 days vs. 109  22 days).
Pre-LVAD Ang I and II and total and cross-linked collagen were similar between groups. Post-LVAD, Ang II was
reduced in the ACE-I group but increased in control subjects (181  7 fmol/g vs. 262  41 fmol/g; p  0.05).
Similarly, cross-linked collagen decreased during LVAD support in the ACE-I group. Left ventricular (LV) mass and
myocardial stiffness were lower in the ACE-I group. ACE-I normalized the LV and right ventricular (RV) MMP-1/
TIMP-1 ratio. Collagen content and characteristics of the RV were not affected by ACE-I.
Conclusions ACE-I therapy was associated with decreased Ang II, myocardial collagen content, and myocardial stiffness dur-
ing LVAD support. This is the first demonstration of a pharmacologic therapy that can impact myocardial proper-
ties during mechanical unloading, and it could foster new lines of investigation in strategies of enhancing myo-
cardial recovery during LVAD support. (J Am Coll Cardiol 2007;49:1166–74) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.071(
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It is widely appreciated that hemodynamic sup-
port and unloading of the heart provided by left
ventricular assist devices (LVADs) have profound
broad-based effects on fundamental properties of
cardiac myocytes of end-stage failing human
hearts (1). Myocardial cell size and left ventricular
rom the *Department of Medicine and †Department of Surgery, College of
hysicians and Surgeons, Columbia University, New York, New York; ‡Department
f Pharmacology, Erasmus Medical Center, Rotterdam, the Netherlands; and §The
ack H. Skirball Center for Cardiovascular Research, Cardiovascular Research
oundation, Orangeburg, New York.c
Manuscript received July 21, 2006; revised manuscript received October 4, 2006,
ccepted October 9, 2006.LV) size and mass approach normal, calcium cycling proper-
ies, and isolated myocardial contractility are improved, and
See page 1175
ene expression patterns and signaling pathways are normal-
zed. These impressive effects have been broadly termed reverse
tructural, functional, and molecular remodeling, respectively
2,3). However, despite these positive effects, LVAD place-
ent does not induce changes in ventricular function that
ermit LVAD removal with sustained cardiac recovery in a
ajority of patients (4,5). Thus far, the only patient groups in
hich promising outcomes are observed are those with myo-arditis or acute cardiogenic shock (6).
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March 20, 2007:1166–74 ACE Inhibitor Therapy During LVAD SupportWe recently showed that prolonged mechanical hemody-
amic unloading increases myocardial tissue levels of angioten-
in (Ang) II with concomitant increases in collagen cross-
inking and elevation in myocardial stiffness (7). This led us to
ypothesize that increased fibrosis occurring during mechani-
al unloading could be a factor in explaining the lack of
orrelation between cellular and whole heart recovery during
VAD support (8,9).
It is known that elevated serum levels of Ang II could be
educed by blocking the renin-angiotensin-aldosterone sys-
em with an angiotensin-converting enzyme inhibitor
ACE-I) (10). This leads to improved cardiac performance
ith reduced cardiovascular death and myocardial infarc-
ion, as shown by the HOPE (Heart Outcome Prevention
valuation) study (11). Therefore, the purpose of the
resent study was to test the hypothesis that ACE-I therapy
uring LVAD support decreases tissue levels of Ang II,
educes myocardial fibrosis, and thus improves myocardial
unction. To understand mechanisms of changes in extra-
ellular matrix properties, the impact of ACE-I on tissue
nhibitor of matrix metalloproteinases (TIMP) and matrix
etalloproteinase (MMP) activity was evaluated.
ethods
yocardial tissue samples were obtained from the LV apex
t the time of LVAD implantation (LVAD core) and
ubsequently at the time of cardiac transplantation from 22
atients after LVAD support (HeartMate VE LVAD,
horatec Corp., Pleasanton, California). Seven of these
atients were receiving ACE-I during LVAD support
ompared with 15 who were not. This was a retrospective
tudy, and the use of ACE-I treatment was based exclu-
ively on the clinical decisions of the primary care physi-
ians. At the time of transplantation, myocardial samples
ere collected from the LV free wall at a region without
acroscopic signs of fibrosis. In addition, LV samples were
ollected from end-stage heart failure patients who were
ransplanted without LVAD support (n  26). To help
ifferentiate the effect of LVAD unloading from the effects
f ACE-inhibition on extracellular matrix (ECM) remod-
ling, myocardial samples were also collected from the right
entricle (RV) at the time of cardiac transplantation from
nd-stage failing hearts with (n 15) and without (n 16)
VAD support. In addition LV and RV samples were
ollected from nonfailing hearts not suitable for cardiac
ransplantation (LV: n  5; RV: n  3). Samples from
onfailing hearts were without ACE-I medication. All
atients from which non-LVAD end-stage failing LV and
V samples were obtained were taking ACE-I. All samples
ere snap-frozen in liquid nitrogen and kept at 80°C for
ater analysis.
In addition, the whole hearts were obtained from these
atients at the time of cardiac transplantation after LVAD
upport for measurement of the ex vivo pressure-volume
elationship and estimation of chamber and myocardial utiffness. The LV trabeculae were
solated from a subset of these
earts and contractile perfor-
ance studied in a muscle bath
s detailed in the subsequent
ext.
This study was performed ac-
ording to the guidelines of the
eclaration of Helsinki. All pro-
edures involving human tissue
se were approved by the institu-
ional review board of the New
ork Presbyterian Medical Cen-
er and Erasmus Medical Center.
ngiotensin I and II myocar-
ial tissue levels. Tissue Ang I
nd II levels were measured after
epPak extraction and high-
erformance liquid chromatogra-
hy (HPLC) separation by ra-
ioimmunoassay (12). A known
mount of 125I-Ang I was added
s an internal standard before the extraction procedure, and
he recovery of 125I-Ang I after HPLC separation was used
o correct for losses (maximally 20% to 30%) that occurred
uring extraction and separation.
MP-1, MMP-9, and TIMP-1 protein content. Heart
amples were homogenized in 1-ml lysis buffer (0.05-mol/l
ris-Cl, 150-mmol/l NaCl, and 1% Triton, pH 8.0). The
omogenate was centrifuged at 3000 g for 20 min at 4°C
nd the supernatant collected. One hundred milliliters of
he supernatant was tested in duplicate for total MMP-1
free and MMP-1/TIMP-1 complexed), MMP-9 (free and
IMP-1–complexed proMMP-9), and TIMP-1 using
nzyme-linked immunosorbent assay kits (Amersham Bio-
rak, Piscataway, New Jersey) following the manufacturer’s
nstructions. Values of MMP-1, MMP-9, and TIMP-1
ere standardized per mg of heart tissue protein.
ollagen characterization. Myocardial collagen can be
ractioned into pepsin-soluble and pepsin-insoluble colla-
ens, the latter reflecting primarily cross-linked collagen.
he myocardial pepsin-soluble collagens were extracted
vernight with 5-mg/ml pepsin in 0.5-mol/l acetic acid.
he soluble and insoluble collagens were separated by
entrifugation at 3,000 g for 10 min at 4°C. The soluble
ollagens included both denatured and undenatured colla-
ens, with the latter quantified by the Sircol collagen assay
it with soluble type I collagen as a standard (Accurate
hemicals, Westbury, New York).
Total myocardial collagen content was assessed by mea-
uring hydroxyproline content using a modified Stegemann
ethod in hydrolyzed total soluble and insoluble collagens
13). The extent of collagen denaturation was assessed by
he content of undenatured collagen and the ratio of
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme
inhibition
Ang  angiotensin
CHF  chronic heart failure
ECM  extracellular matrix
EDPVR  passive end-
diastolic pressure-volume
relationship
LV  left
ventricle/ventricular
LVAD  left ventricular
assist device
MMP  matrix
metalloproteinase
RV  right
ventricle/ventricular
TIMP  tissue inhibitor of
matrix metalloproteinasesndenatured to total soluble collagens. The ratio of insolu-
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ACE Inhibitor Therapy During LVAD Support March 20, 2007:1166–74le to total soluble collagen was calculated and used as a
easure of cross-linking.
assive pressure-volume relationship and estimation of
hamber and myocardial stiffness. The passive LV end-
iastolic pressure-volume relationship (EDPVR) of each
rrested heart was measured as described previously (7). In
rief, all hearts were perfused with cold hypocalcemic
yperkalemic cardioplegic solution at explantation. The
ortic root and the LVAD inflow cannula were clamp-
ccluded. A metal adapter was attached to the mitral
nnulus and a compliant water-filled latex balloon was
laced within the LV chamber. Pressure within the balloon
as measured with a high-fidelity micromanometer as
olume was progressively increased. The pressure was then
lotted as a function of volume at each step, resulting in a
assive pressure-volume relationship equivalent to the end-
iastolic pressure-volume relationship of the beating heart.
hile measuring this relationship in the LV chamber, the
V chamber was emptied. The size of the LV chamber was
ndexed by the volume at which pressure within the ventri-
le reached 30 mm Hg (LVV30).
Ventricular chamber stiffness () was calculated from the
x vivo EDPVRs according to the following equation, as
escribed by Mirsky and Pasipoularides (14):
P · e[·(V⁄Vw)] [1]
here P is pressure, V is volume, Vw is myocardial wall
olume (calculated from measured LV mass and assumed
ensity of 1.05 g/ml),  is the chamber stiffness, and  is a
tiffness constant.
Myocardial stiffness () is the slope of the Ln(stress)
ersus Ln(strain) relationship, for which myocardial stress
nd strain are estimated assuming a spherical geometry of
he heart with an internal radius “a” and an external radius
b” (14). Midwall stress (m) and midwall strain (m) were
alculated according to the following equations:
m 2.03 · P · V ⁄ Vw · [2 · (b ⁄ a) ⁄ (1 (b ⁄ a)]
3 [2]
m (1 ⁄ 2) · [(3 ⁄ 4 · ) · V]
(1⁄3) · (1 b ⁄ a) [3]
(b ⁄ a) (1Vw ⁄ V)
1⁄3 [4]
ecause there is no accepted simple analytical approach for
stimating RV stresses and strains, no attempt was made to
stimate RV myocardial stiffness.
All calculations were performed using commercially avail-
ble software (Igor Pro 4.01, WaveMetrics, Lake Oswego,
regon).
yocardial force generation. Myocardial force data were
btained from LV free wall trabeculae as described previ-
usly (15). In brief, immediately after cardiectomy, trabec-
lae 1 mm in diameter were excised and immersed in
xygenated (95% O2, 5% CO2) ice-cold Krebs-Ringer
olution with 30-mmol/l 2,3-butanedione monoxime. For
b
whe mechanical measurements, the muscle strips were
ounted in a bath with one end connected to a force
ransducer and the other connected to a length-adjustable
icrometer gauge using fine steel hooks. During superper-
usion with 37°C oxygenated Krebs-Henseleit buffer (rate 1
l/l, bath volume 1 ml), trabeculae were stimulated at 1 Hz
nd allowed to equilibrate for at least 1 h at slack length.
fter the resting period, isometric twitches were evoked
ith stimulation voltage 20% above threshold (duration 5
s). The trabeculae were then progressively stretched to the
ength of maximal force generation (Lmax) at 1 Hz fre-
uency. Adequate muscle oxygenation was confirmed as
etailed previously (16). Myocardial force generation was
alculated after normalization to cross-sectional area.
tatistics. Results are presented as mean  SEM. One-
ay analysis of variance (ANOVA) was used to select
ifferences between groups. A Student-Newman-Keuls test
as used for multiple comparisons. A Student t test was
sed for comparison of 2 groups. A paired t test was used for
omparing pre- and post-LVAD samples. The statistical
nalysis was conducted with commercially available statisti-
al software (SPSS 11.5; SPSS, Chicago, Illinois). A p value
f 0.05 was considered to be statistically significant.
esults
atient population and ACE-I medication. Patient de-
ographics of the ACE-I and control LVAD groups are
ummarized in Table 1. Both groups had comparable ages,
ender distributions, heart failure etiologies, and durations
f LVAD support. Except for a lower mean arterial pressure
n the ACE-I group, baseline hemodynamic parameters
efore implant were also comparable. Reasons for LVAD
mplantation were similar in both groups and included
aseline Characteristics
Table 1 Baseline Characteristics
CHF Without
LVAD
LVAD With
ACE-I
LVAD Without
ACE-I
(Control)
n 26 7 15
Age, yrs 51 13 51 17 55 8
Male, % 66* 100 84
DCM, % 57 57 40
LVAD duration, days N/A 109 22 96 65
ACE-I use before LVAD, % 88.7 71.4 73.3
MAP, mm Hg 78.1 10.7 65.7 6.2† 75.5 7.5
PCWP, mm Hg 29.6 12.7 28.0 3.7 25.5 7.0
RAP, mm Hg 13.7 7.0 13.0 6.6 11.8 4.7
CO, l/min 2.84 0.8 3.9 1.1 4.2 1.1
Reason for LVAD
Deterioration on Tx wait list 6 (86%) 12 (80%)
Post-thoracotomy 1 (14%) 1 (7%)
Post-MI cardiogenic shock 0 (0%) 2 (13%)
p 0.05 CHF without LVAD versus ACE-I and control; †p 0.05 versus CHF without LVAD and
ontrol (analysis of variance).
ACE-I angiotensin-converting enzyme inhibition; CHF congestive heart failure; CO cardiac
utput; DCM dilated cardiomyopathy; LVAD left ventricular assist device; MAPmean arterial
lood pressure; MI  myocardial infarction; N/A  not applicable; PCWP  pulmonary capillary
edge pressure; RAP  right arterial pressure; Tx  cardiac transplant.
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March 20, 2007:1166–74 ACE Inhibitor Therapy During LVAD Supportlinical deterioration on the transplant waiting list with need
or increasing doses of inotropic support, cardiogenic shock
fter myocardial infarction, and low output syndrome after
oronary artery bypass graft. The relatively high average
alues of cardiac output were in the setting of preoperative
notropic support in most of the patients.
Eleven of the 15 patients from the control group received
CE-I therapy before LVAD implantation, but this was
ever restarted after LVAD implantation. Five of the 7
atients in the ACE-I group were taking ACE-I before
VAD implantation. The ACE-I used was enalapril, cap-
opril, or lisinopril and was started in this group of patients
pproximately 30 days after LVAD implantation and con-
inued during LVAD support until transplantation (Table
). Other cardiovascular medications used are summarized
n Table 3.
ngiotensin I and II myocardial tissue levels. Compared
ith the pre-LVAD state, in which most patients were
lready receiving ACE-I treatment, myocardial tissue levels
f Ang I significantly increased after LVAD support in both
he ACE-I and the control group (p  0.05) (Table 4).
owever, the increase tended to be lower in the ACE-I
roup. In RV samples (obtained only after LVAD support),
he Ang I levels were nonsignificantly higher in the control
han in the ACE-I group.
In contrast, tissue Ang II levels were significantly reduced
uring LVAD support in the ACE-I group, whereas they
ncreased in the control group (Table 4). The Ang II levels
rom the post-LVAD RV myocardium showed a similar
rend.
rotein levels of MMP-1, MMP-9, and TIMP-1.
MP-1 protein levels increased significantly in end-stage
eart failure despite ACE-I treatment in both LV and RV
p  0.05) (Fig. 1A). After LVAD support, MMP-1
rotein levels trended toward lower levels in patients who
eceived ACE-I. This trend was also observed with
MP-9 levels, but to a lesser extent (Fig. 1B). In contrast,
IMP-1 levels, which was reduced in end-stage heart
ailure, increased tremendously during LVAD support,
specially in the patients receiving ACE-I (p  0.05 vs.
hronic heart failure [CHF]) (Fig. 1C). Thus, the MMP-
/TIMP-1 ratio was normalized during LVAD support by
CE-I treatment (Fig. 1D).
CE-I Medication in LVAD Patients
Table 2 ACE-I Medication in LVAD Patients
Patient # ACE-I* Max. Dose
Duration
(Days)
1 Enalapril 5 mg bid 33
2 Enalapril 12.5 mg bid 56
3 Lisinopril 5 mg qd 20
4 Captopril 25 mg tid 75
5 Lisinopril 10 mg qd 94
6 Captopril 50 mg tid 177
7 Captopril 50 mg tid 217m
Medication started around 30 days after implant.
Abbreviations as in Table 1.ollagen content. In the paired samples from the LV,
yocardial tissue levels of total, soluble, and insoluble
ross-linked collagen significantly increased during LVAD
upport in the control group (p  0.05 vs. pre-LVAD)
Table 4). However, ACE-I therapy was associated with a
ignificant reduction of cross-linked collagen (p  0.05 vs.
re-LVAD) and preserved the increase in total and soluble
ollagen. This reverse remodeling process was not detect-
ble in the RV samples from the ACE-I group, which
howed trends similar to the control group.
DPVR and stiffness. Figure 2 shows group-averaged ex
ivo LV EDPVR from the ACE-I and control groups.
lthough the duration of LVAD support was similar, these
urves shifted leftward toward more normal volumes in both
VAD groups. This trend was more prominent in the
CE-I group, and there was a nearly statistically significant
eduction of LVV30 in the ACE-I group compared with the
ontrol group (140  23 ml vs. 195  13 ml; p  0.06).
urther, there was a significant reduction in LV mass in
CE-I compared with control patients (171  54 g vs. 252
48 g; p  0.05) (Fig. 3). The ACE-I treatment had no
ignificant effect on RV ex vivo EDPVR or mean RVV30.
The dimensionless chamber stiffness constant  was not
ffected by ACE-I treatment in the LV or RV (Table 5).
owever, calculated LV myocardial tissue stiffness was
ignificantly lower in the ACE-I group than in the control
roup (p  0.05) (Table 5).
yocardial force generation. To assess whether there was
ny functional consequence of differences in collagen con-
ent, isolated muscle strips were superfused at baseline
onditions and during beta-adrenergic stimulation with
soproterenol. Figure 4 shows that developed force was
imilar in muscle strips after LVAD support with and
ithout ACE-I treatment both in basal state and after
eta-adrenergic stimulation.
iscussion
eft ventricular assist device-induced hemodynamic un-
oading in patients with end-stage heart failure induces
everse structural remodeling (leftward shift of the EDPVR
nd reduced LV mass) but is associated with increases in
eneral Medication in Both LVAD Groups
Table 3 General Medication in Both LVAD Groups
Medication
LVAD Without
ACE-I, %
(n  15)
LVAD With
ACE-I, %
(n  7)
ACE-I* 0 100
Beta-blocker 0 0
Amiodarone 13 29
Ca channel antagonist 7 14
Digitalis 13 29
Diuretics 40 43
Mineralocorticoid receptor antagonist 13 0
For individual ACE-I medications, see Table 2.
Abbreviations as in Table 1.yocardial Ang II levels, total and cross-linked collagen,
a
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o
r
d
d
A
A e-LVAD
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ACE Inhibitor Therapy During LVAD Support March 20, 2007:1166–74nd myocardial tissue stiffness. These changes in ECM
epresent a further pathological progression beyond that
bserved in end-stage heart failure alone. Such changes are
Figure 1 MMP1- and TIMP-1 Protein Expression
Matrix metalloproteinase (MMP)-1 (A), MMP-9 (B), and tissue inhibitor of MMP (TI
angiotensin-converting enzyme inhibition (ACE-I) (solid bars), and left ventricular as
bars). Whereas MMP-1 protein levels are slightly reduced in LV samples after LVA
pared with CHF hearts without LVAD support. The MMP-1/TIMP-1 ratio (D) shows
0.05 versus normal hearts; †p  0.05 versus CHF  ACE-I (analysis of variance).
ngiotensin I and II Measurements and Collagen Characterization
Table 4 Angiotensin I and II Measurements and Collagen Chara
Normal
(LV n  5; RV n  3)
CHF  ACE-I
(LV n  26; RV n  1
Ang I
LV 97 13 275 74
RV 129 6 181 48
Ang II
LV 106 16 129 31
RV 161 22 217 51
Total collagen
LV 4.17 0.16 8.21 3.4
RV 5.51 0.59 6.15 0.41
Soluble collagen
LV 3.61 0.15 6.61 1.6
RV 4.68 0.28 5.63 0.32
Cross-linked collagen
LV 0.56 0.15 2.68 1.4
RV 1.37 0.15 2.21 0.41
ng I and II measurements in fmol/g; all collagen measurements in 	g/mg; *p 0.05 versus pr
Ang  angiotensin; LV  left ventricle; RV  right ventricle; other abbreviations as in Table 1.elatively unique in that almost all other aspects of myocar-
ial properties that have been studied change toward normal
uring LVAD support. We have therefore speculated that
(C) protein levels in normal (open bars), chronic heart failure (CHF) 
evice (LVAD)-supported hearts without ACE-I (blue bars) and with ACE-I (red
ort and ACE-I, TIMP-1 protein levels are significantly elevated in this group com-
toward better normalization after LVAD support if patients received ACE-I. *p 
left ventricle; RV  right ventricle.
ization
LVAD Without ACE-I (Control) LVAD With ACE-I
Pre-LVAD
(n  15)
Post-LVAD
(n  15)
Pre-LVAD
(n  7)
Post-LVAD
(n  7)
49 8 653 310* 54 9 261 52*
N/A 631 260 N/A 444 281
109 39 262 41* 163 64 81 7*†
N/A 212 57 N/A 77 12
8.3 1.38 10.8 1.49* 6.9 0.71 5.3 0.73†
N/A 8.5 0.79 N/A 8.3 0.92
3.8 0.71 5.3 0.72* 4.0 1.06 3.3 0.63
N/A 5.9 0.52 N/A 5.5 0.47
5.9 1.05 8.4 1.10* 6.4 0.76 5.4 0.63*
N/A 5.5 1.66 N/A 5.4 1.90
(same group, paired t test); †p 0.05 versus post-LVAD (control, analysis of variance).MP)-1
sist d
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March 20, 2007:1166–74 ACE Inhibitor Therapy During LVAD Supporthe ECM should be a target for improving the frequency
nd extent of recovery during LVAD support.
We demonstrated that ACE-I therapy during LVAD
upport enhances reverse structural remodeling in the LV
further shifts toward normal of the EDPVR and greater
ass reductions) while reducing tissue Ang II concentra-
ion, normalizing the MMP-1/TIMP-1 ratio, and decreas-
ng total and cross-linked collagen and myocardial stiffness.
he data from the RV samples show that ACE-I also
educed myocardial tissue levels of Ang II and normalized
he MMP-1/TIMP-1 ratio in that chamber as well, but RV
ollagen content remained elevated. Additionally, ACE-I
herapy did not impact RV mass or chamber size. Combin-
ng this information from the LV and the RV leads to the
onclusion that mechanical unloading combined with
Figure 2 EDPVRs With and Without ACE-I
Grouped end-diastolic pressure-volume relationships (EDPVR) measured ex vivo
from whole hearts. The average EDPVR from patients with LVAD support receiv-
ing ACE-I (LVAD ACE-I, open circles) tended to be shifted to the left toward
lower volumes compared with the EDPVR from patients with LVAD support with-
out ACE-I (LVAD Control, solid circles). X  nonfailing hearts; solid squares 
failing hearts without LVAD support. *p  0.05 versus CHF without LVAD (anal-
ysis of variance). Abbreviations as in Figure 1.
Figure 3 Impact of ACE-I on LV and RV Volume and LV Mass
(Left) LV (black bars) and RV (green bars) ex vivo volume at the pressure of 30 m
control group. (Right) LV mass was significantly lower in the ACE-I group (open ba
 0.062 versus control group (Student t test). Abbreviations as in Figure 1.CE-I are required to normalize myocardial fibrosis, and
yocardial mass regression is more prominent during
VAD support in the presence of ACE-I treatment. As
uch, these findings indicate that the regulation of the ECM
uring LVAD support is more complex than previously
hought and involves a complex interaction of mechanical
nd neurohormonal factors. Additionally, it is observed that
espite these substantial beneficial effects on the ECM,
CE-I therapy had no detectable effect on the myocardial
orce generation in isolated trabeculae.
It is noteworthy that our findings indicated that a
eduction in load and reduction of tissue Ang II levels were
oth necessary to prevent fibrosis. This is provocative and
eserves further study for verification; however we propose
hat, in addition to Ang II, other, potentially dual-
egulated, upstream factors could be involved.
Although it is well documented that ACE-I therapy and
ther drugs can dramatically reduce cardiac fibrosis and
mpact on cardiac structure and function (17), the effects of
uch treatments in the setting of LVAD support are not
reviously understood. At a functional level, these changes
ere associated with a decrease in LV myocardial stiffness,
eflecting the fundamental changes in myocardial material
roperties. The LV chamber stiffness, however, was not
hanged. This is not surprising, because chamber stiffness
ndexes lumped properties of the entire LV, which is
etermined not only by myocardial stiffness but also by
yocardial mass, chamber size, and chamber geometry. In
his case, LVAD-induced changes in LV mass and size
ounteract changes in myocardial stiffness such that net
hamber stiffness is not affected.
There is a major gap between the overwhelmingly bene-
cial impact of prolonged LVAD support on myocardial
ellular properties and the very low rate of recovery of
ardiac function to the point where the native heart is once
gain able to support the circulation, thus obviating the
eed for transplantation. Even when such weaning is
. With ACE-I therapy, LV volume was almost significantly lower compared with the
pared with the control group (solid bar). *p  0.05 versus LV control group; †pm Hg
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ACE Inhibitor Therapy During LVAD Support March 20, 2007:1166–74ossible, heart function frequently deteriorates and patients
equire transplant, reinsertion of another LVAD, or suc-
umb to complications of heart failure (4,5,18).
In an attempt to enhance the rate and sustainability of
ardiac functional recovery during LVAD support, investi-
ators in Harefield employ a high dose of the selective
2-adrenergic receptor agonist clenbuterol along with beta-
locker, ACE-I, angiotensin-receptor blockade, and aldo-
terone in combination with a special LVAD weaning
rotocol (the so-called Harefield protocol). With this ap-
roach, these investigators were able to successfully wean
ore than two-thirds of all LVAD-supported patients (19).
he rationale underlying this approach was the intent to use
lenbuterol to induce physiologic myocardial hypertrophy
nd thus improve cardiac contractility. However, other
actors have been implicated as well. For example, Terrac-
iano et al. (20) recently showed that specific changes in
Figure 4 Developed Force Measured
From Isolated Myocardial Trabeculae
Developed force (mN/mm2) at baseline (open bars) and during -stimulation
with isoproterenol (solid bars) in the control and ACE-I groups. Whereas isopro-
terenol significantly increases developed force, there is no difference between
the control and the ACE-I groups. *p  0.001 versus baseline (Student t test).
Abbreviations as in Figure 1.
tiffness Measurements
Table 5 Stiffness Measurements
Normal
(LV n  5; RV n  3) (
Chamber stiffness, 
LV 11.50 4.22
RV 6.39 0.12
Myocardial stiffness,  (mm Hg · ml)
LV 26.67 3.80
RV N/A
p 0.05 versus LVAD (control) and CHF  ACE-I (analysis of variance).
Abbreviations as in Tables 1 and 4.dxcitation-contraction coupling appeared to be associated
ith this clinical recovery. In another recent publication,
arton et al. (21) showed that clenbuterol increased insulin-
ike growth factor I messenger RNA in cardiac myocytes in
hese patients and may limit atrophy and apoptosis during
everse remodeling. The fact that these patients are receiv-
ng a host of drugs with a multitude of effects renders it
mpossible to conclude that one drug or another is respon-
ible for recovery or by which mechanism such treatments
ight be working.
Furthermore, long-term experience after LVAD removal
n these patients is not yet available, so the sustainability of
he recovery has yet to be confirmed. In addition, a similar
rotocol tested in LVAD patients at Columbia University
as not able to show any improvement in cardiac function
ith this regimen, and no patients could be weaned from
he LVAD (22,23).
Accumulating experimental evidence suggests that in-
reased cardiac collagen concentration is coincident with a
arked deterioration of systolic and diastolic function (24).
ross-linked collagen especially appeared to be involved in
nd-stage heart failure remodeling (25). Factors contribut-
ng to potentially deleterious ECM remodeling during
VAD support have recently been shown by our group (7)
nd in part confirmed by another group (26). Bruggink et al.
26) found that LVAD increased ECM volume in the first
00 days. Owing to changes in the ratio between MMP-1
nd TIMP-1 and increased myocardial tissue Ang and
ngiotensinogen levels, collagen degradation is decreased,
eading to these further abnormal ECM changes during
VAD support.
The data concerning effects on the RV show that the
eduction in myocardial Ang II and the normalization of the
MP-1/TIMP-1 ratio was a global effect of oral ACE-I.
owever, the RV data further show that, although ACE-I
herapy is able to prevent deleterious collagen increase in the
V during LVAD support, the collagen remodeling in the
V was not significantly affected. The impact of ACE-I
herapy to reduce RV tissue Ang II levels but not RV
ollagen or RV size may be at odds with the current
hinking that in experimental settings, nonhypotensive
HF  ACE-I
26; RV n  16)
LVAD Without ACE-I
(Control) LVAD With ACE-I
Post-LVAD (n  15) Post-LVAD (n  7)
6.52 4.22 8.89 2.99 7.54 3.98
9.66 2.87 8.33 0.81 9.07 0.53
0.30 8.31 31.29 5.84 23.02 5.84*
N/A N/A N/AC
LV n 
3oses of ACE-I inhibitors can decrease collagen content.
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March 20, 2007:1166–74 ACE Inhibitor Therapy During LVAD Supportowever, one important difference between those experi-
ental settings (in which hemodynamic load is normal) and
he RV of LVAD supported patients is that the RV of the
VAD patients is hemodynamically overloaded. Therefore,
t is possible that the ongoing mechanical stimulation
verrides the effect of ACE-I with regard to regulation of
ollagen metabolism.
In addition, despite changes in collagen content, there
as no detectable difference in contractile performances of
uscle strips isolated from post-LVAD hearts with or
ithout ACE-I therapy. It is not certain whether such in
itro preparations are sensitive and reliable enough to detect
hat may be a subtle but clinically significant impact on
yocardial function. If true, however, this finding would be
n contrast to the popular notion that fibrosis by itself can
ndependently impair myocardial function (27). Although
yocardial force generation was unaltered by ACE-I treat-
ent, this does not indicate that treatment had no effect on
verall cardiac performance. As discussed in the preceding
ext, ACE-I treatment prevented dysfunctional matrix
hanges which can decrease the effectiveness of myocyte
ontraction. It is conceivable that myocyte alignment may
ave been modified in a manner that would permit more
ffective force generation in the hearts of LVAD patients
eceiving ACE-I.
tudy limitations. This was a retrospective observational
tudy, not a randomized interventional study, which results
n several limitations. First, the decision of which patients
eceived ACE-I treatment after LVAD implant was based
n clinical grounds (i.e., development of hypertension)
hich could introduce a selection bias. It is significant that
aseline clinical features, myocardial Ang content, and
ollagen characteristics were similar between the 2 groups.
urthermore, conventional wisdom would suggest that
yocardial collagen content and cross-linking would be
ignificantly increased in the setting of hypertension. The
undamental finding that collagen content and cross-linking
ere decreased in the LVAD ACE-I group suggests that
his selection bias was not a factor, but this conclusion is not
ertain.
Second, it is generally assumed that abnormally increased
ollagen content and cross-linking which result in increased
yocardial stiffness are in general detrimental to cardiac
unction. All patients in the present study were trans-
lanted, and no functional assessment of recovery or at-
empt to wean LVAD support was performed. Although we
emonstrate ACE-I–mediated reversal of ECM changes,
o assessment of the impact of these changes on LV
unction in vivo has been made in these patients. Therefore,
t cannot be concluded that these changes confer any benefit
o pump function or, most importantly, patient hemody-
amics. The findings of the lack of impact on myocardial
unction would suggest that if any such benefit were to be
nduced, they would more likely be mediated by beneficial
ffects on heart structure than on myocardial function, but at
he present a definitive conclusion cannot be made.Third, we make the assumption that the impacts of 3
ifferent ACE-Is used in these patients (enalapril, captopril,
nd lisinopril) are equivalent with regard to effect on ECM
emodeling.
Finally, in calculating myocardial stiffness, the same
quation is applied to normal, failing, and post-LVAD
earts. The chamber geometry may be different between
hese conditions, and it is possible that the results could be
nfluenced by such changes and therefore may not solely
eflect changes in intrinsic myocardial material properties.
onclusions
t is provocative that among the dozens of myocardial
roperties that have been examined after LVAD support
structural, cellular, molecular, and biochemical) the only
ajor cardiac feature yet identified that does not return
oward normal is the ECM (7,8,28,29). It is therefore
mportant to understand whether such ECM changes con-
ribute to the lack of global ventricular recovery that limits
he ability to wean LVAD support in a vast majority of
atients. Left ventricular assist device support is associated
ith increased myocardial content of Ang II, disruption of
he MMP-1/TIMP-1 balance, and increased myocardial
ollagen cross-linking and myocardial stiffness. These effects
re reversed by ACE-I therapy. This finding highlights the
mportance of understanding specific effects of different
harmacologic agents that may be used during LVAD
upport. Such understanding might lead to rational drug
ombinations that could optimize the chances of global
yocardial recovery and facilitate the use of LVADs as a
ridge to recovery.
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